Purple Biotech Ltd.

Regulatory Filings • Oct 3, 2023

6K- Purple Biotech Reports Positive Interim andPreliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer false

���� ����� ��"�	2 380
PURPLE BIOTECH LTD
Corporation no: 520031238	12724
- - -

	Israel Securities Authority			Tel Aviv Stock Exchange		C002 ( Public )		Reported via MAGNA:	03/10/2023
	www.isa.gov.il			www.tase.co.il				Reference:	2023-02-112317	Time of broadcast: 15:02 15:02

---

Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

	The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report on6K- Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer

ea186226-6k_purplebioEDGAR1_Bannerless_isa.pdf

����� ������ �� ������ �������� �� ������ ������ ����� ��� ����� �� NT219
References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
- - -
Stock Exchange/Market: NASDAQ CM	Date of revision of form structure: 08/08/2023
Address: Oppenheimer, Science Park 4 , Rehovot 7670104   , Israel Tel: 03-9333121 , 03-9311321 Fax: 03-5097196
E-mail address: ir@purple-biotech.com   Company site: www.kitovpharma.com
Previous names of reporting entity: KITOV PHARMA LTD, KITOV PHARMACEUTICALS HOLDINGS LTD, MAINROM LINE LOGISTICS LTD, ORLINE DEVELOPMENT AND INVESTMENT LTD, KADURY & HAI (MOLET) ASSETS & INVESTMENTS LTD,
Name of the Signatory: Masas Ludmer Adi Position of Signatory in the reporting corporation: Company Controller Name of Employer Company:
Address: Menachem Begin Drive 132 , Tel Aviv 6701101 Telephone: 03-9333121 Facsimile: 03-5097196 E-mail: adim@kitovpharma.com 1
Israel